Thioredoxin in cancer-Role of histone deacetylase inhibitors

Seminars in Cancer Biology

Volumn 16, Issue 6, 2006, Pages 436-443

  Marks, Paul A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Histone deacetylase; Histone deacetylase inhibitors; Suberoylanilide hydroxamic acid; Thioredoxin; Thioredoxin binding proteins

Indexed keywords

BINDING PROTEIN; CYTOKINE; DOXORUBICIN; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; REACTIVE OXYGEN METABOLITE; SUBEROYLANILIDE HYDROXAMIC ACID; THIOREDOXIN; VASCULOTROPIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; B CELL LYMPHOMA; CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER PATIENT; CANCER RESISTANCE; CELL CYCLE ARREST; CELL DEATH; CELL MIGRATION; CELL PROLIFERATION; COLON CANCER; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; DISEASE MARKER; DOWN REGULATION; DRUG BINDING; DRUG MECHANISM; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; GENE CONTROL; HUMAN; LUNG NON SMALL CELL CANCER; MALIGNANT TRANSFORMATION; PHEOCHROMOCYTOMA; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN STABILITY; REVIEW; STRUCTURE ANALYSIS; T CELL LEUKEMIA;

ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; NEOPLASMS; THIOREDOXIN;

EID: 33751185927     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2006.09.005     Document Type: Review

References (93)

1. Arner E.S., and Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem 267 20 (2000) 6102-6109
2. Bjornstedt M., Kumar S., Bjorkhem L., Spyrou G., and Holmgren A. Selenium and the thioredoxin and glutaredoxin systems. Biomed Environ Sci 10 2-3 (1997) 271-279
3. Powis G., Mustacich D., and Coon A. The role of the redox protein thioredoxin in cell growth and cancer. Free Radic Biol Med 29 3-4 (2000) 312-322
4. Wakasugi N., Tagaya Y., Wakasugi H., et al. Adult T-cell leukemia-derived factor/thioredoxin, produced by both human T-lymphotropic virus type I- and Epstein-Barr virus-transformed lymphocytes, acts as an autocrine growth factor and synergizes with interleukin 1 and interleukin 2. Proc Natl Acad Sci USA 87 21 (1990) 8282-8286
5. Blum H., Rollinghoff M., and Gessner A. Expression and co-cytokine function of murine thioredoxin/adult T cell leukaemia-derived factor (ADF). Cytokine 8 1 (1996) 6-13
6. Oblong J.E., Berggren M., Gasdaska P.Y., and Powis G. Site-directed mutagenesis of active site cysteines in human thioredoxin produces competitive inhibitors of human thioredoxin reductase and elimination of mitogenic properties of thioredoxin. J Biol Chem 269 16 (1994) 11714-11720
7. Nakamura H., Masutani H., Tagaya Y., et al. Expression and growth-promoting effect of adult T-cell leukemia-derived factor. A human thioredoxin homologue in hepatocellular carcinoma. Cancer 69 8 (1992) 2091-2097
8. Gasdaska J.R., Berggren M., and Powis G. Cell growth stimulation by the redox protein thioredoxin occurs by a novel helper mechanism. Cell Growth Differ 6 12 (1995) 1643-1650
9. Gallegos A., Gasdaska J.R., Taylor C.W., et al. Transfection with human thioredoxin increases cell proliferation and a dominant-negative mutant thioredoxin reverses the transformed phenotype of human breast cancer cells. Cancer Res 56 24 (1996) 5765-5770
10. Nakamura H., Matsuda M., Furuke K., et al. Adult T cell leukemia-derived factor/human thioredoxin protects endothelial F-2 cell injury caused by activated neutrophils or hydrogen peroxide. Immunol Lett 42 1-2 (1994) 75-80
11. Matsuda M., Masutani H., Nakamura H., et al. Protective activity of adult T cell leukemia-derived factor (ADF) against tumor necrosis factor-dependent cytotoxicity on U937 cells. J Immunol 147 11 (1991) 3837-3841
12. Cromlish J.A., and Roeder R.G. Human transcription factor IIIC (TFIIIC). Purification, polypeptide structure, and the involvement of thiol groups in specific DNA binding. J Biol Chem 264 30 (1989) 18100-18109
13. Bannister A.J., Cook A., and Kouzarides T. In vitro DNA binding activity of Fos/Jun and BZLF1 but not C/EBP is affected by redox changes. Oncogene 6 7 (1991) 1243-1250
14. Matthews J.R., Wakasugi N., Virelizier J.L., Yodoi J., and Hay R.T. Thioredoxin regulates the DNA binding activity of NF-kappa B by reduction of a disulphide bond involving cysteine 62. Nucleic Acids Res 20 15 (1992) 3821-3830
15. Makino Y., Yoshikawa N., Okamoto K., et al. Direct association with thioredoxin allows redox regulation of glucocorticoid receptor function. J Biol Chem 274 5 (1999) 3182-3188
16. Abate C., Patel L., Rauscher III F.J., and Curran T. Redox regulation of fos and jun DNA-binding activity in vitro. Science 249 4973 (1990) 1157-1161
17. Hirota K., Matsui M., Iwata S., Nishiyama A., Mori K., and Yodoi J. AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc Natl Acad Sci USA 94 8 (1997) 3633-3638
18. Saitoh M., Nishitoh H., Fujii M., et al. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. Embo J 17 9 (1998) 2596-2606
19. Powis G., Kirkpatrick D.L., Angulo M., and Baker A. Thioredoxin redox control of cell growth and death and the effects of inhibitors. Chem Biol Interact 111-112 (1998) 23-34
20. Kakolyris S., Giatromanolaki A., Koukourakis M., et al. Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer. Clin Cancer Res 7 10 (2001) 3087-3091
21. Kim H.J., Chae H.Z., Kim Y.J., et al. Preferential elevation of Prx I and Trx expression in lung cancer cells following hypoxia and in human lung cancer tissues. Cell Biol Toxicol 19 5 (2003) 285-298
22. Han H., Bearss D.J., Browne L.W., Calaluce R., Nagle R.B., and Von Hoff D.D. Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res 62 10 (2002) 2890-2896
23. Nishiyama A., Masutani H., Nakamura H., Nishinaka Y., and Yodoi J. Redox regulation by thioredoxin and thioredoxin-binding proteins. IUBMB Life 52 1-2 (2001) 29-33
24. Choi J.H., Kim T.N., Kim S., et al. Overexpression of mitochondrial thioredoxin reductase and peroxiredoxin III in hepatocellular carcinomas. Anticancer Res 22 6A (2002) 3331-3335
25. Freeman R.E., and Neuzil J. Role of thioredoxin-1 in apoptosis induction by alpha-tocopheryl succinate and TNF-related apoptosis-inducing ligand in mesothelioma cells. FEBS Lett 580 11 (2006) 2671-2676
26. Nishinaka Y., Nishiyama A., Masutani H., et al. Loss of thioredoxin-binding protein-2/Vitamin D3 up-regulated protein 1 in human T-cell leukemia virus type I-dependent T-cell transformation: implications for adult T-cell leukemia leukemogenesis. Cancer Res 64 4 (2004) 1287-1292
27. Kim S.J., Miyoshi Y., Taguchi T., et al. High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer. Clin Cancer Res 11 23 (2005) 8425-8430
28. Welsh S.J., Bellamy W.T., Briehl M.M., and Powis G. The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Res 62 17 (2002) 5089-5095
29. Nishiyama A., Matsui M., Iwata S., et al. Identification of thioredoxin-binding protein-2/Vitamin D(3) up-regulated protein 1 as a negative regulator of thioredoxin function and expression. J Biol Chem 274 31 (1999) 21645-21650
30. Chen K.S., and DeLuca H.F. Isolation and characterization of a novel cDNA from HL-60 cells treated with 1,25-dihydroxyvitamin D-3. Biochim Biophys Acta 1219 1 (1994) 26-32
31. Nakamura H. Thioredoxin as a key molecule in redox signaling. Antioxid Redox Signal 6 1 (2004) 15-17
32. Butler L.M., Zhou X., Xu W.-S., et al. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. PNAS 99 18 (2002) 11700-11705
33. Ikarashi M., Takahashi Y., Ishii Y., Nagata T., Asai S., and Ishikawa K. Vitamin D3 up-regulated protein 1 (VDUP1) expression in gastrointestinal cancer and its relation to stage of disease. Anticancer Res 22 6C (2002) 4045-4048
34. Ohta S., Lai E.W., Pang A.L., et al. Downregulation of metastasis suppressor genes in malignant pheochromocytoma. Int J Cancer 114 1 (2005) 139-143
35. de Vos S., Hofmann W.K., Grogan T.M., et al. Gene expression profile of serial samples of transformed B-cell lymphomas. Lab Invest 83 2 (2003) 271-285
36. Escrich E., Moral R., Garcia G., Costa I., Sanchez J.A., and Solanas M. Identification of novel differentially expressed genes by the effect of a high-fat n-6 diet in experimental breast cancer. Mol Carcinog 40 2 (2004) 73-78
37. Li H., Kantoff P.W., Giovannucci E., et al. Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer. Cancer Res 65 6 (2005) 2498-2504
38. Schulze P.C., De Keulenaer G.W., Yoshioka J., Kassik K.A., and Lee R.T. Vitamin D3-upregulated protein-1 (VDUP-1) regulates redox-dependent vascular smooth muscle cell proliferation through interaction with thioredoxin. Circ Res 91 8 (2002) 689-695
39. Junn E., Han S.H., Im J.Y., et al. Vitamin D3 up-regulated protein 1 mediates oxidative stress via suppressing the thioredoxin function. J Immunol 164 12 (2000) 6287-6295
40. Takahashi Y., Nagata T., Ishii Y., Ikarashi M., Ishikawa K., and Asai S. Up-regulation of Vitamin D3 up-regulated protein 1 gene in response to 5-fluorouracil in colon carcinoma SW620. Oncol Rep 9 1 (2002) 75-79
41. Kim K.Y., Shin S.M., Kim J.K., Paik S.G., Yang Y., and Choi I. Heat shock factor regulates VDUP1 gene expression. Biochem Biophys Res Commun 315 2 (2004) 369-375
42. Dutta K.K., Nishinaka Y., Masutani H., et al. Two distinct mechanisms for loss of thioredoxin-binding protein-2 in oxidative stress-induced renal carcinogenesis. Lab Invest 85 6 (2005) 798-807
43. Kobayashi T., Uehara S., Ikeda T., Itadani H., and Kotani H. Vitamin D3 up-regulated protein-1 regulates collagen expression in mesangial cells. Kidney Int 64 5 (2003) 1632-1642
44. Han S.H., Jeon J.H., Ju H.R., et al. VDUP1 upregulated by TGF-beta1 and 1,25-dihydorxyvitamin D3 inhibits tumor cell growth by blocking cell-cycle progression. Oncogene 22 26 (2003) 4035-4046
45. Lehrmann H., Pritchard L.L., and Harel-Bellan A. Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation. Adv Cancer Res 86 (2002) 41-65
46. Luger K., Mader A.W., Richmond R.K., Sargent D.F., and Richmond T.J. Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 389 6648 (1997) 251-260
47. Marks P.A., and Dokmanovic M. Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin Investig Drugs 14 12 (2005) 1497-1511
48. Fischle W., Wang Y., and Allis C.D. Binary switches and modification cassettes in histone biology and beyond. Nature 425 6957 (2003) 475-479
49. Spotswood H.T., and Turner B.M. An increasingly complex code. J Clin Invest 110 5 (2002) 577-582
50. Zhang Y., and Reinberg D. Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. Genes Dev 15 18 (2001) 2343-2360
51. Minucci S., and Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6 1 (2006) 38-51
52. De Ruijter A.J., Van Gennip A.H., Caron H.N., Kemp S., and Van Kuilenburg A.B. Histone deacetylases: characterization of the classical HDAC family. Biochem J 370 Pt (2002) 737-749
53. Blander G., and Guarente L. The Sir2 family of protein deacetylases. Annu Rev Biochem 73 (2004) 417-435
54. Bhalla K.N. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol 23 17 (2005) 3971-3993
55. Drummond D.C., Noble C.O., Kirpotin D.B., Guo Z., Scott G.K., and Benz C.C. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 45 (2005) 495-528
56. Richon V.M., Emiliani S., Verdin E., et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 95 6 (1998) 3003-3007
57. Butler L.M., Agus D.B., Scher H.I., et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 60 18 (2000) 5165-5170
58. Marks P., Rifkind R.A., Richon V.M., Breslow R., Miller T., and Kelly W.K. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1 3 (2001) 194-202
59. Miller T.A., Witter D.J., and Belvedere S. Histone deacetylase inhibitors. J Med Chem 46 24 (2003) 5097-5116
60. Kelly W.K., Richon V.M., O'Connor O., et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 9 10 Pt 1 (2003) 3578-3588
61. Ruefli A.A., Ausserlechner M.J., Bernhard D., et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA 98 19 (2001) 10833-10838
62. Kelly W.K., O'Connor O.A., Krug L., et al. Phase I study of the oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), in patients with advanced cancer. J Clin Oncol 23 17 (2005) 3923-3931
63. Atadja P., Gao L., Kwon P., et al. Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824. Cancer Res 64 2 (2004) 689-695
64. Yoshida M., Matsuyama A., Komatsu Y., and Nishino N. From discovery to the coming generation of histone deacetylase inhibitors. Curr Med Chem 10 22 (2003) 2351-2358
65. Finnin M.S., Donigian J.R., Cohen A., et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401 6749 (1999) 188-193
66. Somoza J.R., Skene R.J., Katz B.A., et al. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure (Camb) 12 7 (2004) 1325-1334
67. Zhang C., Richon V., Ni X., Talpur R., and Duvic M. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol 125 5 (2005) 1045-1052
68. O'Connor O.A., Heaney M.L., Schwartz L., et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol (2005)
69. Kelly W., and Marks P. Drug Insight: histone deacetylase inhibitors-development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol 2 3 (2005) 150-157
70. Dokmanovic M., and Marks P.A. Prospects: histone deacetylase inhibitors. J Cell Biochem 96 (2005) 293-304
71. McKinsey T.A., Kuwahara K., Bezprozvannaya S., and Olson E.N. Class II histone deacetylases confer signal responsiveness to the ankyrin-repeat proteins ANKRA2 and RFXANK. Mol Biol Cell 17 1 (2006) 438-447
72. Gray S.G., Qian C.N., Furge K., Guo X., and Teh B.T. Microarray profiling of the effects of histone deacetylase inhibitors on gene expression in cancer cell lines. Int J Oncol 24 4 (2004) 773-795
73. Jose B., Oniki Y., Kato T., Nishino N., Sumida Y., and Yoshida M. Novel histone deacetylase inhibitors: cyclic tetrapeptide with trifluoromethyl and pentafluoroethyl ketones. Bioorg Med Chem Lett 14 21 (2004) 5343-5346
74. Peart M.J., Smyth G.K., van Laar R.K., et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci USA 102 10 (2005) 3697-3702
75. Marks P.A., Miller T., and Richon V.M. Histone deacetylases. Curr Opin Pharmacol 3 4 (2003) 344-351
76. Piekarz R., and Bates S. A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. Curr Pharm Des 10 19 (2004) 2289-2298
77. Curtin M., and Glaser K. Histone deacetylase inhibitors: the abbott experience. Curr Med Chem 10 22 (2003) 2373-2392
78. Gui C.Y., Ngo L., Xu W.S., Richon V.M., and Marks P.A. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci USA 101 5 (2004) 1241-1246
79. Chambers A.E., Banerjee S., Chaplin T., et al. Histone acetylation-mediated regulation of genes in leukaemic cells. Eur J Cancer 39 8 (2003) 1165-1175
80. Richon V.M., Sandhoff T.W., Rifkind R.A., and Marks P.A. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 97 18 (2000) 10014-10019
81. Ungerstedt J.S., Sowa Y., Xu W.S., et al. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA 102 3 (2005) 673-678
82. Rosato R.R., Almenara J.A., and Grant S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res 63 13 (2003) 3637-3645
83. Aguilaniu H., Gustafsson L., Rigoulet M., and Nystrom T. Asymmetric inheritance of oxidatively damaged proteins during cytokinesis. Science 299 5613 (2003) 1751-1753
84. Budihardjo I., Oliver H., Lutter M., Luo X., and Wang X. Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol 15 (1999) 269-290
85. Liu X., Kim C.N., Yang J., Jemmerson R., and Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 86 1 (1996) 147-157
86. Thornberry N.A., and Lazebnik Y. Caspases: enemies within. Science 281 5381 (1998) 1312-1316
87. Jiang X., and Wang X. Cytochrome c-mediated apoptosis. Annu Rev Biochem 73 (2004) 87-106
88. Hail Jr. N. Mitochondria: a novel target for the chemoprevention of cancer. Apoptosis 10 4 (2005) 687-705
89. Peart M.J., Tainton K.M., Ruefli A.A., et al. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res 63 15 (2003) 4460-4471
90. Shao L., Diccianni M.B., Tanaka T., et al. Thioredoxin expression in primary T-cell acute lymphoblastic leukemia and its therapeutic implication. Cancer Res 61 19 (2001) 7333-7338
91. Shao Y., Gao Z., Marks P.A., and Jiang X. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 101 (2004) 18030-18035
92. Yu C., Subler M., Rahmani M., et al. Induction of apoptosis in BCR/ABL+ cells by histone deacetylase inhibitors involves reciprocal effects on the RAF/MEK/ERK and JNK pathways. Cancer Biol Ther 2 5 (2003) 544-551
93. Mantovani R. A survey of 178 NF-Y binding CCAAT boxes. Nucleic Acids Res 26 5 (1998) 1135-1143